News & Events about Vor Biopharma Inc.
Globe Newswire
2 months ago
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO(rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. ...
Globe Newswire
3 months ago
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: H.C. Wainwright Cell Therapy Virtual ConferenceFireside Chat recording available ...
Globe Newswire
3 months ago
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of MylotargMylotarg treatment enriched CD33-negative donor hematopoiesisSecond patient successfully received trem-cel transplant and achieved neutrophil engraftment and platelet recovery CAMBRIDGE, Mass., Feb. 16...
Globe Newswire
4 months ago
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in ...
Globe Newswire
4 months ago
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities 3rd Annual Oncology Conference. B. Riley Securities 3rd Annual Oncology Conference Fireside...